Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data
Open Access
- 17 February 2022
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (8) , 921-943
Abstract
Summary: Background: The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB). However, resistance to ETV has been reported, especially with prior exposure to other NAs, and long‐term TDF treatment has been associated with decline in renal function and loss of bone mineral density in some patients. Consequently, TAF may be preferable to ETV, TDF or other NAs in specific circumstances such as in patients with risk of bone or renal complications, elderly patients or those with previous NA experience.Aim: To provide a summary of the available efficacy and safety data following switch to TAF from other NAs in patients with CHB in clinical studies and real‐world settings.Methods: Literature searches were performed on PubMed and abstracts from three major international liver congresses between 2019 and 2021. Studies that included efficacy and/or safety data for patients with CHB switching from any NA to TAF were selected.Results: Thirty‐six papers and abstracts were included in this narrative review. Switching from TDF to TAF maintained or improved virological and biochemical responses with improved bone and renal safety. Switching from ETV or other NAs to TAF maintained or improved virological and biochemical responses and varying results for bone and renal safety.Conclusions: Switching to TAF appears to maintain or improve virological, biochemical and bone‐ and renal‐related safety outcomes. These data support the concept of switching to TAF in some patients with CHB based on their individual circumstances.Keywords
Funding Information
- Gilead Sciences
This publication has 75 references indexed in Scilit:
- Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort StudyGastroenterology, 2014
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionHepatology, 2012
- Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial RespondersDigestive Diseases and Sciences, 2012
- Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340Molecular Pharmaceutics, 2012
- High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV LoadGastroenterology, 2012
- Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2012
- Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavirJournal of Viral Hepatitis, 2011
- Trends in Body Weight and Overweight in the U.S. PopulationNutrition Reviews, 2009
- Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic TissueAntimicrobial Agents and Chemotherapy, 2005
- Weight Gain Continues in the 1990s: 10-year Trends in Weight and Overweight from the CARDIA StudyAmerican Journal of Epidemiology, 2000